secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001935979-25-000056
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting
--------------------------------------------------------------------------------

- FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).
- FDA plans to hold an advisory committee meeting to discuss the application; no date set.
- FDA did not raise new concerns; mid-cycle review found no major safety issues and no REMS needed.
- Troriluzole has Fast-Track, Orphan Drug, and Priority Review status; would be first approved SCA treatment.
- Clinical data showed 50-70% slowing of disease progression and reduced fall risk in SCA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/0001935979-25-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer